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A B S T R A C T
Background: Epidemiologic studies suggest that diabetes is associated with an increased risk of cancer.
Concurrently, clinical trials have shown that metformin, which is a first-line antidiabetic drug, displays antic-
ancer activity. The underlying mechanisms for these effects are, however, still not well recognized.
Methods: Methods based on atomic force microscopy (AFM) were used to directly evaluate the influence of
metformin on the nanomechanical and adhesive properties of endothelial and cancer cells in chronic hy-
perglycemia. AFM single-cell force spectroscopy (SCFS) was used to measure the total adhesion force and the
work of detachment between EA.hy926 endothelial cells and A549 lung carcinoma cells. Nanoindentation with a
spherical AFM probe provided information about the nanomechanical properties of cells, particularly the length
and grafting density of the glycocalyx layer. Fluorescence imaging was used for glycocalyx visualization and
monitoring of E-selectin and ICAM-1 expression.
Results: SCFS demonstrated that metformin attenuates adhesive interactions between EA.hy926 endothelial cells
and A549 lung carcinoma cells in chronic hyperglycemia. Nanoindentation experiments, confirmed by confocal
microscopy imaging, revealed metformin-induced recovery of endothelial glycocalyx length and density. The
recovery of endothelial glycocalyx was correlated with a decrease in the surface expression of E-selectin and
ICAM-1.
Conclusion: Our results identify metformin-induced endothelial glycocalyx restoration as a key factor responsible
for the attenuation of adhesion between EA.hy926 endothelial cells and A549 lung carcinoma cells.
General significance: Metformin-induced glycocalyx restoration and the resulting attenuation of adhesive inter-
actions between the endothelium and cancer cells may account for the antimetastatic properties of this drug.
1. Background
Metformin is a first-line antidiabetic drug that decreases blood
glucose concentration and improves insulin sensitivity. Although the
mechanism of its activity is still not well recognized [1], its pre-
dominant effect on glucose metabolism is mostly attributed to direct
inhibition of mitochondrial respiratory complex I in hepatocytes, sup-
pression of gluconeogenesis and augmentation of glycolysis. A met-
formin-induced drop in the ATP/AMP ratio may also activate AMPK,
eventually disrupting gluconeogenesis and lipogenesis gene expression
[2]. Experimental studies have shown that metformin, beyond its pri-
mary action, exerts a protective effect on endothelial cells (ECs) and the
cardiovascular system. It prevents EC apoptosis [3] and premature se-
nescence [4], enhances activation of endothelial nitric oxide synthase
(eNOS) [5,6] and attenuates overexpression of adhesion molecules on
ECs [6]. Metformin reduces infarct size [7] and counteracts en-
doplasmic reticulum stress, oxidative stress and vasorelaxation im-
pairment [5]. It is suggested that these effects can also be achieved
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independently of glucose and lipid metabolism [5]. Moreover, treat-
ment of rodents with metformin was shown to extend their lifespan
[8,9], but there are also studies contradicting these findings [10,11].
The clinical data demonstrate beneficial effects of metformin in patients
with type 2 diabetes (T2D), as it lowers the risk of all-cause mortality
[12,13]. However, its impact on the risk of cardiovascular diseases
remains uncertain, especially in nondiabetic patients [1,14].
Clinical trials documented that T2D is associated with an increased
risk of cancer development and worse disease outcome [15,16]. Hy-
perglycemia boosts cancer cell metabolism and promotes their pro-
liferation, invasiveness and metastasis [17]. Moreover, hyper-
insulinemia may contribute to cancer progression through insulin
receptor and insulin-like growth factor signaling [16]. Long-term clin-
ical studies indicate that metformin may exert anticancer properties. It
was shown to reduce the risk of cancer and decrease cancer mortality in
patients with T2D [18–21]. The detailed mechanisms are not entirely
clear, however. Molecularly, the anticancer activity of metformin can
be related to both AMPK-dependent and AMPK-independent effects,
including mainly mTOR and IGF-1 signaling inhibition (broadly re-
viewed by Pernicova & Korbonits [22]). Furthermore, metformin exerts
anti-angiogenic properties, which may also contribute to the reduction
of tumor growth [23]. In our study, we focused on the antimetastatic
potential of metformin, the mechanism of which has been poorly un-
derstood thus far.
Cancer metastasis is a multiphase process, with a crucial step of
crossing the endothelial barrier by the cancer cell, involving direct in-
teractions of the cancer cell and the endothelium [24]. Such cell-to-cell
interactions, similar to leukocyte-endothelial interactions, are regulated
by the glycocalyx, a protective polysaccharide layer forming a physical
and functional barrier, found on the apical part of the endothelium
[25]. In hyperglycemic conditions, the endothelial glycocalyx layer is
reduced [26], which may facilitate the adhesion of circulating cells to
the activated endothelium [27]. In accordance, our recent study shows
that short-term hyperglycemia induces changes in both the mechanical
and structural properties of the endothelial glycocalyx, which in turn
modulates the adhesion of cancer cells to the endothelium [28].
Atomic force microscopy (AFM) is a useful tool for studying the
nanomechanical and adhesive properties of cells due to its ability to
control interactions between two objects within a range of nanonewton
(nN) forces. Using single-cell force spectroscopy (SCFS), it is possible to
investigate adhesive interactions between single cells directly [29,30].
Moreover, the AFM nanoindentation method enables the measurement
of the length and density of the glycocalyx layer as well as the elastic
properties of the cell body. In this work, we used AFM methods to verify
whether metformin can attenuate the adhesion of cancer cells to the
endothelium and, if so, whether it can be achieved by regulating en-
dothelial glycocalyx properties.
2. Methods
2.1. Cell culture
Human lung carcinoma A549 (ATCC, UK) cells were cultured in F-
12 K medium (Cat. No. 30–2004, ATCC) supplemented with 10% fetal
bovine serum (FBS, Cat. No. 10082–147, Invitrogen). EA.hy926
(ATCC), immortalized human umbilical vein endothelial cells, were
grown in Dulbecco's modified Eagle's medium with 25 mM glucose
(high glucose, HG) (Cat. No. 30–2002, ATCC), 10% FBS (Cat. No.
10082–147, Invitrogen) and 2% HAT supplement (Cat. No. 21060–017,
Invitrogen). The cells were maintained in standard conditions at 37 °C,
5% CO2, and 95% humidity.
2.2. Experimental scheme
EA.hy926 cells were seeded in DMEM HG supplemented with 10%
FBS and 2% HAT at a density of 104 cells/mL on sticky-slides I 0.6 (Cat.
No. 80188, IBIDI) covered with fibronectin and were kept in static
conditions for 24 h to allow their attachment. After this time, slides
were inserted into the fluidic unit (IBIDI pump system for simulation of
blood vessels), and the cells were subjected to a laminar shear stress of
20 dyn/cm2 for 48 h (Fig. S1AeC). To prepare A549 cells for the AFM
measurements, the cells were plated in F-12 K medium supplemented
with 10% FBS and 25 mM glucose. Both cell lines were treated with
metformin either for 72 h (short-term) or additionally pretreated for
12 days (long-term) (Fig. S1D). Heparinase (1000 U/mL, Sigma) was
added to the cells for the last 30 min of incubation with metformin
(short-term experimental scheme).
2.3. AFM study of the nanomechanics and cell-to-cell adhesion
All AFM measurements were performed using a NanoWizard 3
NanoScience AFM commercial instrument (JPK Instruments, Germany).
The nanoindentation measurements with a spherical (colloidal) probe
(Novascan, USA) were used to detect the endothelial glycocalyx and
determine the apparent elastic modulus of ECs (Fig. S2A). We used a
sphere probe with a diameter of 4.5 μm attached to the cantilever with
a spring constant of 0.02 N/m. Force–distance curves were obtained
with an indentation velocity of 0.7 μm/s and a maximal force of 1 nN.
The measurements were performed on living cells in Hanks' Balanced
Salt Solution (H8264, Sigma-Aldrich) supplemented with 25 mM glu-
cose and 1% FBS, with or without 10 μM metformin. Experiments were
conducted on the top of ECs (central part; deformation of the cell up to
10% of the cell height was applied to avoid the potential influence of
the underlying nucleus).
To determine glycocalyx parameters as well as the elastic modulus,
we used a procedure proposed by Sokolov et al. [31] (Fig. S2B). In the
Sokolov's model, it is assumed that the surface of the cell is not
homogenous, and it consists of an inner elastic body covered with the
outer cellular brush. Such a brush model implies that a well-defined
spherical AFM probe at first indents the cellular brush (squeezes the
brush), and next the probe indents the cell body. Therefore, non-linear
deformation of the brush could be analyzed by a fit based on the
Alexander-de Gennes' theory of polymer brushes [31,32]. Following the
procedure described in our recent paper [28], initially the Hertz model
was fitted to the part of the curve close to the maximal force load (blue
curve), for which the glycocalyx is assumed to be almost squeezed.
Next, the brush model was fitted to the F(h) curve (Fig. S2B inset) to
calculate the length and grafting density of the glycocalyx layer. The
grey area shows a range of fit (Fig. S2B inset). Additionally, the as-
sumption of total squeezing of the glycocalyx layer has been verified
experimentally by measuring the dependence of the elastic modulus on
the applied load (see Fig. S2C in Supplementary Information). For load
forces higher than 0.8 nN, the saturation of the elastic modulus de-
pendence on the applied force was observed.
Single-cell force spectroscopy (SCFS) study was conducted to eval-
uate the interactions between the A549-EA.hy926 system (see
Supplementary Information Fig. S3A). Adhesive measurements were
carried out using a V-shaped cantilever with a spring constant of
0.01 N/m (MLCT O-10, Bruker). The methodology of SCFS measure-
ments was described in detail in our previous work [28]. In brief, tipless
cantilevers were covered with 50 μg/mL fibronectin (Sigma-Aldrich)
and were stored in PBS. To immobilize a single cancer cell on the
cantilever, a functionalized cantilever was brought into contact for 30 s
with a loosely bound cell. Next, a cantilever with a single cancer cell
was immediately taken for measurements. The adhesive interactions
between A549 and EA.hy926 cells were measured in Hanks' Balanced
Salt Solution (H8264, Sigma-Aldrich) supplemented with 25 mM glu-
cose and 1% FBS, with or without 10 μM metformin. Experiments were
conducted on the central part of the cell. Fig. S3B presents an ex-
emplary graph of a typical force-distance F(Z) curve obtained during
the adhesive study. Measurement began when the cantilever with at-
tached living cancer was separated from ECs, and it approached the
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monolayer of EA.hy926 cells at 1.9 μm/s until a preset contact force of
1.4 nN was reached (grey curve). After a defined contact time of 2 s, the
cantilever was retracted at a velocity of 1.9 μm/s (black curve). The
contact time and contact force were controlled experimentally (see
Supplementary Information Fig. S3C and S3D). It proceeded as follows:
at first, the adhesion force was measured as a function of the contact
time or the contact force. Next, based on these measurements, the va-
lues of contact time and contact force were chosen from the range, for
which the adhesion force did not change significantly. The total adhe-
sion force (Fd) and work of detachment (Wd) were extracted from the
retraction curve using the JPK data processing software. The total ad-
hesion force Fd was described as the maximal force required to detach
A549 cells from EA.hy926 cells and was calculated as the outermost
point on the adhesive curve. It should be noted that the Fd parameter
characterizes only the net adhesive interactions between two cells,
without discrimination of specific and non-specific interactions. The
work of detachment is presented as the area between the contour of the
retraction curve and the baseline. We defined the rupture events as
unbinding events occurring for a small cell-cell separation distance,
which are associated with the breakage of bonds involving surface
molecules. The number of rupture events means the number of un-
binding events detected per single curve.
2.4. AFM imaging
The AFM imaging was performed using V-shaped gold-coated can-
tilevers (MLCT, Veeco Probes, Camarillo, CA, USA) with a nominal
spring constant of 0.01 N/m. All experiments were performed with
nonfixed cells in Hanks' Balanced Salt Solution (H8264, Sigma-Aldrich)
supplemented with 25 mM glucose and 1% FBS. Images (256 × 256
pixels) were obtained at a scan size of 60 × 60 μm2 at a scan rate of
0.4 Hz. Between 10 and 15 images of cells were obtained for each
sample.
2.5. Phalloidin staining
For each fluorescence experiment, ECs were grown on 24-well
plates and stimulated with 10 μM metformin for 72 h or 360 h. Before
staining, the culture medium was removed from wells, the cells were
rinsed with warm PBS and then were fixed with 3.6% formaldehyde
(Sigma) for 10 min at room temperature. Next, the cells were rinsed
three times with warm buffer and permeabilized with 0.1% Triton X
(Invitrogen-Thermo Fisher) for 4 min, followed by blocking in PBS
containing 1% BSA (Invitrogen-Thermo Fisher) for 30 min. Again, the
cells were rinsed with PBS and incubated with phalloidin conjugated
with Alexa Fluor 488 dye (1:8000, Molecular Probes) for 20 min. Before
the measurement, the cells were rinsed twice with PBS. Fluorescence
images were obtained using an Olympus IX71 with a 20× air objective
and were recorded and processed with Olympus CellSense software.
Samples were excited with an Olympus X-Cite Q120 lamp and filtered
by an Olympus U-MWIB2 filter.
2.6. Cell viability assay
Cell viability was evaluated by Trypan blue (Life Technologies). In
the beginning, ECs were trypsinized, and Trypan blue (0.2%) was added
to the cell suspension (at a ratio of 1:5). The prepared suspension of
cells was placed on a glass slide, covered with a glass coverslip, and
incubated for 3 min at RT. After this time, the set of images was per-
formed using an optical microscope (Olympus IX71) equipped with
Olympus CellSense software (version 1.41). The viable and dead cells
were counted. Cell viability is presented as the percentage of viable
cells in the population of cells.
2.7. Expression of E-selectin and ICAM-1
EA.hy926 cells were cultured on 24-well black plates. Cells were
fixed with methanol for 5 min at−10 °C. Next, they were gently rinsed
with PBS and incubated with blocking peptide solution (sc-516214,
Santa Cruz Biotechnology) for 30 min. After this time, they were wa-
shed three times with PBS. For E-selectin staining, the cells were in-
cubated with E-Selectin antibody (10 μg/mL, sc-137054, Santa Cruz
Biotechnology) conjugated with Alexa Fluor 488 for 12 h. Nuclei were
counterstained with Hoechst (Thermo Fisher). For ICAM-1 staining,
cells were incubated with anti-ICAM-1 antibody conjugated with Alexa
Fluor 488 (5 μg/mL, Santa Cruz Biotechnology) for 1 h, followed by
nuclear staining with Hoechst (Thermo Fisher). The fluorescence in-
tensity was measured using a fluorescence Microplate Reader (Infinite
M200 PRO, Tecan).
2.8. Glycocalyx visualization
The cells were grown on 24-well plates and stimulated with 10 μM
metformin for 72 h and 360 h. After the appropriate time, cells were
fixed with paraformaldehyde (3.8%, Sigma) for 10 min. Next, cells were
gently rinsed in PBS three times and incubated with blocking peptide
solution (Santa Cruz Biotechnology) for 30 min. After this time, they
were washed three times in PBS and incubated with biotinylated wheat
germ agglutinin (WGA, Vector Laboratories) or Maackia amurensis
lectin II (MAL II, Vector Laboratories) for 30 min. Next, cells were
washed three times and incubated with avidin conjugated with Alexa
Fluor 546. Cell nuclei were stained with Hoechst (Thermo Fisher).
Images were taken using a Zeiss LSM710 confocal microscope and the
original software by Zeiss.
2.9. Statistical analysis
The AFM nanoindentation and SCFS, as well as the fluorescence
intensity data are presented in the form of box plots [the box represents
the standard deviation (SD) and whiskers represent the range of the 5th
to 95th percentile]. Statistical significance was tested using two-way
ANOVA (p < .05), with independent variables being the time of in-
cubation and sample type, i.e., control (ctr) or metformin (met).
ANOVA was followed by Tukey's multiple comparison tests. Since the
AFM data were log-normally distributed, we performed data transfor-
mation using a natural logarithm, in order to use the ANOVA statistical
test (see Fig. S4 in Supplementary Information). This analysis was ap-
plied to all AFM data. The means (blue line in all scatter plots) of the
logarithmically transformed data were then back-transformed using the
procedure described by Limpert et al. [33]. In the manuscript, all data
was shown as a non-transformed raw data in order to show the real
spread of data points as well as the skewness of the distributions.
3. Results
3.1. Metformin attenuates cancer cell-endothelium adhesive interactions
EA.hy926 immortalized endothelial cells were selected as an ex-
perimental model because, in contrast to primary endothelial cells
[34,35], they tolerate continuous culture in hyperglycemic conditions
(25 mM) well. In our previous paper, we have shown that the sustained
growth of EA.hy926 cells in high glucose (HG) concentrations causes a
gradual increase in their stiffness [36]. Therefore, the study was carried
out on the cells presenting stable elastic modulus values and nano-
mechanical properties (between 57 and 72 days of culture in HG)
(Fig. 1A, S1D). A nontoxic concentration of metformin (10 μM) was
selected for the subsequent experiments (Fig. 1B). No cytotoxic effect at
this concentration was also observed for A549 cells. The effect of
metformin was checked in two experimental settings. For the short-
term studies, EA.hy926 cells were exposed to metformin for 72 h, of
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which 24 h were under static conditions to allow their attachment after
plating and another 48 h were in laminar flow, followed by AFM
measurements and other analyses, while for the long-term effects, the
cells were additionally pretreated with metformin for 12 days. A549
cells were exposed to metformin in HG medium for 72 h or 15 days in
static conditions.
We observed that the longer the time of EA.hy926 cell culture in HG
conditions is, the stronger the adhesion interactions between cancer
cells and the endothelium are (Fig. 2), as indicated by the increased
total adhesion force (Fig. 2A), work of detachment (Fig. 2B) and the
frequency of rupture force events (Fig. 2C). Both short- and long-term
treatment of ECs and A549 cells with metformin caused a decrease in all
inspected parameters (Fig. 2A-C). The total adhesion force, the work of
detachment and the frequency of rupture force remained significantly
increased in the group treated with metformin cultured for a longer
time in HG in comparison to short-time incubation (Fig. 2). These re-
sults show that metformin can counteract adhesive interactions be-
tween ECs and cancer cells in hyperglycemic conditions. Moreover, the
force and work needed for cancer cell and endothelial cell detachment
are higher for the cells incubated longer in HG conditions, regardless of
metformin treatment.
3.2. Metformin facilitates endothelial glycocalyx barrier regeneration
Our previous studies demonstrated that culture of ECs and cancer
cells in prolonged hyperglycemic conditions causes gradual reduction
of the glycocalyx layer [28]. As depicted in Fig. 3, the treatment of cells
with metformin restored the glycocalyx parameters in comparison to
control cells. Grafting density of the glycocalyx layer, but not its length,
significantly increased in response to short-term exposure of ECs to
metformin (Fig. 3A, B). Long-term treatment of ECs with metformin
improved both the grafting density of the glycocalyx layer and the
length of the glycocalyx brush (Fig. 3A, B). These results were fully
corroborated by fluorescent imaging. Staining of ECs with wheat germ
agglutinin (WGA), binding sialic acid and N-acetylglucosaminyl re-
sidues, which are present on ECs [37], revealed that both short- and
long-term incubation of ECs with metformin increased these glycocalyx
components (Fig. 3C-F, K). Additionally, binding of Maackia amurensis
lectin II (MAL II), which recognizes sialic acid, was augmented in re-
sponse to metformin treatment, regardless of the exposure time
(Fig. 3G-J, L).
Moreover, firm and clearly visible actin fibres were observed for the
cells cultured in HG conditions (Fig. 4A, C, E, G), in accordance with the
Fig. 1. Specification of the experimental model.(A) Time-dependent changes in the elastic modulus of endothelial cells growing in HG conditions. Arrows mark
the time-points selected for experiments, for which stable values of the elastic modulus were observed. n = 3 experiments, N = 15 cells. (B) Viability assay
performed for different concentrations of metformin in HG concentration. n= 2 experiments, N= 40 cells. One-way ANOVA followed by Tukey's posttest, ⁎p < .05,
⁎⁎p < .01. Ctr – vehicle.
Fig. 2. Metformin attenuates the adhesive interactions between cancer cells and the endothelium. (A) Total adhesion force n = 2 experiments, N = 8 cells,
(B) work of detachment n = 2 experiments, N = 8 cells and (C) frequency of rupture events n = 2 experiments, N = 8 cells. The numbers in brackets indicate the
total number of curves taken into analysis. Two-way ANOVA followed by Tukey's posttest, ⁎p < .05, ⁎⁎p < .01, ⁎⁎⁎p < .001. (ns) nonsignificant. Ctr – vehicle.
EA.hy926 and A549 cells were cultured in HG conditions with or without 10 μM metformin.
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Fig. 3. Metformin induces glycocalyx restoration. (A) Glycocalyx grafting density, n = 4 experiments, N = 14 cells. (B) Length of endothelial glycocalyx layer,
n = 4 experiments, N= 14 cells. Representative pictures of endothelial cells stained by WGA lectin (red)/phalloidin (green) (CeF) and MAL II lectin (red)/phalloidin
(green) (G-J). Quantitative data of (K) WGA, N = 30 cells, and (L) MAL II, N = 36 cells, mean fluorescence intensity. The numbers in brackets indicate the total
number of curves taken into analysis. Two-way ANOVA followed by Tukey's posttest. ⁎p < .05, ⁎⁎p < .01, ⁎⁎⁎p < .001. (ns) nonsignificant. Ctr – vehicle. EA.hy926
cells were cultured in HG under flow conditions with or without 10 μM metformin .
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increased cellular stiffness (Fig. 4I), which is mainly determined by the
structure of the actin cytoskeleton [38]. Treatment of ECs with met-
formin reduced the stiffness of the cells and actin polymerization
(Fig. 4B, D, F, H, I). Thus, we conclude that metformin normalizes the
nanomechanical properties of endothelial cells and facilitates glyco-
calyx barrier reconstruction.
3.3. Cancer cell glycocalyx is modulated by metformin
In the next step, we checked whether metformin affects cancer cell
glycocalyx. Glycocalyx grafting density and length were slightly de-
creased and increased, respectively, after 72 h-exposure of A549 cells to
metformin in HG (Fig. 5A,B). In contrast to glycocalyx length, its
grafting density was strongly increased by prolonged incubation of
A549 cells in HG conditions, and no further metformin-induced changes
were observed (Fig. 5A,B). The fluorescent visualization of the glyco-
calyx by WGA and MAL II lectins in A549 cells confirmed that both
metformin and long-exposure to HG facilitated the coverage of the cell
by glycocalyx (Fig. 5C-L). In contrast to endothelial cells (Fig. 4I),
metformin increased the cancer cell stiffness (Fig. 5M). These data
indicate that metformin can modulate the glycocalyx barrier and cell
elasticity both in endothelial and cancer cells.
3.4. The endothelial glycocalyx impairs the adhesive interactions of ECs
with cancer cells
To assess whether inhibition of EC-cancer interactions by metformin
results from its effect on the endothelial or tumor cell, we performed
analysis of the total adhesion force, the work of detachment, and the
frequency of rupture force events between endothelial and cancer cells
in the experimental setting, where ECs, but not A549 cells, were ex-
posed to metformin. The experiments revealed that the pattern of total
adhesion force, work of detachment and frequency of rapture events
between the cancer cell and endothelium (Fig. 6) is similar to that seen
when both cell types were stimulated with metformin (Fig. 2).
It is plausible, therefore, that metformin-induced attenuation of
endothelial-cancer cell interactions is rather related to its influence on
endothelial cells, but not on cancer cells. Consequently, we hypothe-
sized that the inhibitory effects of metformin on the cancer cell-en-
dothelium adhesive interactions are mediated by endothelial glycocalyx
Fig. 4. Metformin reduces endothelial cell stiffness and alters actin architecture. (A-D) Representative pictures of actin fibres. N = 35 cells. (E-H)
Representative pictures of AFM images of the structure of the actin cytoskeleton in the EC cortex. N = 35 cells. (I) Elastic modulus values. n = 4 experiments, N = 14
cells. The numbers in brackets indicate the total number of curves taken into analysis. Two-way ANOVA followed by Tukey's posttest. ⁎p < .05, ⁎⁎p < .01,
⁎⁎⁎p < .001. (ns) nonsignificant. Ctr – vehicle. EA.hy926 cells were cultured in HG under flow conditions with or without 10 μM metformin.
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regeneration. To address this question, ECs were treated with hepar-
inase, to selectively shed heparan sulfate from the glycocalyx, to
counteract the metformin-induced recovery of the glycocalyx. The
glycocalyx length (Fig. 7A) and grafting density (Fig. 7B) decreased in
cells treated with heparinase. Both the total adhesion force and work of
detachment between endothelial and cancer cells, as well as the
Fig. 5. Metformin affects the glycocalyx in A549
cells. (A) Glycocalyx grafting density (n = 2 ex-
periments, N = 9 cells). (B) Length of glycocalyx
layer (n = 2 experiments, N = 9 cells).
Representative pictures of A549 cells stained by
WGA lectin (red)/phalloidin (green) (CeF) and MAL
II lectin (red)/phalloidin (green) (G-J). Quantitative
data of (K) WGA (N = 36 cells), and (L) MAL II
(N = 41 cells) mean fluorescence intensity. (M)
Elastic modulus values. n = 2 experiments, N = 10
cells. The numbers in brackets (A,B) indicate the
total number of curves taken into analysis. Two-way
ANOVA followed by Tukey's posttest. *p < .05,
**p < .01. (ns) nonsignificant. Ctr – vehicle. A549
cells were cultured in HG conditions with or without
10 μM metformin.
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Fig. 6. Metformin attenuates adhesive interactions between the cancer cell and endothelium. (A) Total adhesion force n = 3 experiments, N = 11 cells, (B)
work of detachment n = 3 experiments, N = 11 cells and (C) frequency of rupture events n = 3 experiments, N = 11 cells. Numbers in brackets indicate a total
number of curves taken into analysis. Two-way ANOVA followed by Tukey's post-test, *p < .05, **p < .01, ***p < .001. (ns) non-significant. Ctr – vehicle.
EA.hy926 cells were cultured in HG under flow conditions with or without 10 μM metformin. A549 cells were cultured in HG conditions and were not exposed to
metformin.
Fig. 7. Enzymatic degradation of the glycocalyx reverses the effect of metformin on the adhesive interactions between cancer cells and the endothelium.
(A) Glycocalyx length, n = 2 experiments, N = 10 cells, (B) Glycocalyx grafting density, n = 2 experiments, N = 10 cells, (C) Total adhesion force, n = 2
experiments, N = 10 cells, (D) Work of detachment, n = 2 experiments, N = 10 cells. (E) Frequency of rupture events, n = 2 experiments, N = 10 cells. Numbers in
brackets indicate the total number of curves considered in the analysis. Two-way ANOVA followed by Tukey's posttest. ⁎p < .05, ⁎⁎p < .01, ⁎⁎⁎p < .001. (ns)
nonsignificant. eHep – heparinase, Ctr – vehicle. EA.hy926 cells were cultured in HG under flow conditions with or without 10 μM metformin. A549 cells were
cultured in HG conditions and were not exposed to metformin.
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frequency of rupture force events, were heavily increased in response to
heparinase treatment in cells cultured in the presence of metformin
(Fig. 7C-E).
These results show that metformin-stimulated regeneration of the
glycocalyx may be responsible for the attenuation of cancer cell-en-
dothelium adhesive interactions. This effect can also be facilitated by
the metformin-induced downregulation of surface expression of the
adhesion molecules ICAM and E-selectin (Fig. 8A, B) on endothelial
cells. Both mechanisms may contribute to the antimetastatic effect of
metformin observed in vivo.
4. Discussion
The significance of metformin as a potential anticancer therapy
remains controversial because experimental studies are not entirely
consistent with population-based analyses [22]. Taking into con-
sideration the pleiotropic activity of metformin and the mechanisms
that have not been fully understood yet [1], and, on the other hand,
promising results of some clinical reports [22], further detailed ex-
perimental and clinical studies with a mechanistic approach are needed
to obtain a clear answer regarding the anticancer potential of this drug.
In light of data showing the antimetastatic properties of metformin, a
decreased rate of distant metastasis and distant metastasis-free survival
in comparison to non-metformin diabetic patients with prostate cancer
[39], as well as inhibition of metastasis of ovarian tumors and mela-
noma in mice treated with metformin [23,40], we aimed to verify by
direct measurement on a single cell level if metformin can inhibit
cancer cell-endothelium adhesive interactions. In this study, we report
that metformin attenuates the adhesion of cancer cells to the en-
dothelium by improving the nanomechanical properties of endothelial
cells, in particular by restoring the endothelial glycocalyx layer in
chronic hyperglycemia. Thus, this mechanism may contribute to the
antimetastatic effects of metformin.
Glycocalyx tightly covers the cell surface and shields adhesion
molecules from interactions with other cells [41]. Increased exposition
of membrane proteins (i.e., adhesive molecules) contributes not only to
the adhesion of leukocytes but also to cancer cells [42–44]. Injury of
this layer on endothelial cells in hyperglycemia was previously reported
as a cause of endothelial dysfunction development [26,45,46].
Prolonged hyperglycemia results in increased surface expression of
adhesion molecules, adhesive interactions with circulating cells and
higher endothelial permeability for cells and molecules [47]. Accord-
ingly, the reduction of the endothelial glycocalyx layer modulates the
adhesion of cancer cells to the endothelium [28]. As we show here,
treatment of endothelial cells cultured in hyperglycemic conditions
with metformin reduces the total adhesion force and the work of de-
tachment for cancer cells, which is related to changes occurring on the
cell surface, including decreased surface expression of E-selectin and
ICAM and reconstruction of the glycocalyx layer. As the most visible
effect was noted for the glycocalyx grafting density, it seems that
metformin stimulates “de novo” synthesis of glycocalyx molecules in
endothelial cells. The structure of the glycocalyx and its functionality
are restored in response to metformin by increasing the content of N-
acetylglucosamine (GlcNAc) and sialic acid on the cell surface. The
increase in GlcNAc content is mainly related to the structural restora-
tion of the glycocalyx layer by reconstruction of the GAG chains [48].
However, an increase in sialic acid in the glycocalyx may influence cell
function. Sialic acid is one of the terminal monosaccharides which
controls vascular permeability [49]. In hyperglycemia, sialic acid is
shed from the endothelial cell surface into the plasma and is regarded as
a predictive biomarker of diabetic complications [50]. The molecule of
sialic acid in physiological conditions is negatively ionized. Therefore,
it forms a net negative charge on the cell surface, which protects en-
dothelial cells from adhesive interactions with circulating cells [51].
The effect of metformin on endothelial glycocalyx was previously
studied by Eskens et al. in db/db mice [45]. The authors have reported
that metformin causes partial recovery of diabetes-associated disrup-
tion of the glycocalyx barrier and therefore regulates endothelial per-
meability [45], which is in accordance with studies performed on
pulmonary microvascular endothelial cells [52] and in mice [44]. The
literature reports that metformin alleviates endothelial dysfunction
mainly by increasing NO production, inhibiting inflammatory pathways
and regulating mitochondrial ROS production [2,3,53]. Our data in-
dicate that metformin also improves the nanomechanical properties of
ECs, which may affect the functionality of ECs, as endothelial stiffening
is one of the symptoms of endothelial dysfunction and is related to the
attenuation of NO production [54]. In contrast, the reduction of cell
stiffness leads to improved endothelial function and, consequently,
Fig. 8. Surface level of adhesion molecules on endothelial cells (A) E-selectin level, n = 6 experiments. (B) ICAM-1 level, n = 6 experiments. Two-way ANOVA
followed by Tukey's posttest. ⁎p < .05, ⁎⁎p < .01, ⁎⁎⁎p < .001. (ns) nonsignificant. EA.hy926 cells were cultured in HG conditions with or without 10 μM
metformin.
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increased or stabilized NO production by the endothelium [54].
5. Conclusions
In conclusion, we showed that metformin has a beneficial impact on
endothelial cells and reduces the interactions between cancer cells and
the endothelium in chronic hyperglycemia. Metformin improves en-
dothelial glycocalyx properties, increases its length and grafting density
and restores sialic acid and GlcNAc components, which, in turn, may
inhibit the adhesive interactions of endothelial cells with cancer cells.
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